Survival Benefit of Statins in Hemodialysis Patients Awaiting Renal Transplantation

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Angiology

• Publication date

  2015-03-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0035-1547373PMID 26060381PMCID PMC4452604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and

  2012cited by this paper
• Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates

  2012cited by this paper
• Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease

  2012cited by this paper
• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

  2011cited by this paper
• Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients.

  2011cited by this paper
• Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.

  2011cited by this paper
• Rosuvastatin in diabetic hemodialysis patients.

  2011cited by this paper
• Pleiotropic Effects of Sevelamer Beyond Phosphate Binding in End-Stage Renal Disease Patients

  2011cited by this paper
• No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment.

  2010cited by this paper
• Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.

  2009cited by this paper
• Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart With Established Left Ventricular Hypertrophy

  2009cited by this paper
• Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

  2009cited by this paper
• Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

  2008cited by this paper
• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.

  2008cited by this paper
• Association between serum lipids and survival in hemodialysis patients and impact of race.

  2007cited by this paper
• Propensity Scores in Cardiovascular Research

  2007cited by this paper
• Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome.

  2007cited by this paper
• Lipoprotein metabolism and lipid management in chronic kidney disease.

  2007cited by this paper
• Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.

  2007cited by this paper
• K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.

  2005cited by this paper
• Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

  2005cited by this paper
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

  2005cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

  2004cited by this paper
• Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis.

  2004cited by this paper
• Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease

  2004cited by this paper
• Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients.

  2004cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.

  2003cited by this paper
• Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency

  2003cited by this paper
• HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Left ventricular hypertrophy in the renal patient.

  2001cited by this paper
• Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure.

  2001cited by this paper
• Simvastatin Exerts Both Anti-inflammatory and Cardioprotective Effects in Apolipoprotein E—Deficient Mice

  2001cited by this paper
• Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation.

  2000cited by this paper
• SIMVASTATIN INHIBITS CARDIAC HYPERTROPHY AND ANGIOTENSIN‐CONVERTING ENZYME ACTIVITY IN RATS WITH AORTIC STENOSIS

  1999cited by this paper
• Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor.

  1999cited by this paper
• Apolipoprotein C-III, Hypertriglyceridemia and Triglyceride-Rich Lipoproteins in Uremia

  1999cited by this paper
• Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure.

  1999cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.

  1998cited by this paper
• Effects of different dialysis membranes on lipid and lipoprotein serum profiles in hemodialysis patients.

  1995cited by this paper
• High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients.

  1995cited by this paper
• Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure.

  1992cited by this paper
• Impact of left ventricular hypertrophy on survival in end-stage renal disease.

  1989cited by this paper
• Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial

  year unknowncited by this paper

• Adaptation of 2016 European Society of Cardiology/European Atherosclerosis Society guideline for lipid management to Indian patients – A consensus document

  2018influential citation
• Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation

  2018cites this paper
• Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients

  2016cites this paper